Business Wire

NTT-DATA

8.2.2024 09:01:34 CET | Business Wire | Press release

Share
NTT DATA Report Signals a Paradigm Shift as Banks Finally Migrate from Mainframes to AI-driven Cloud Technologies

NTT DATA, a global digital business and IT services leader, today announced a new global banking research report entitled "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure.” The research has unveiled findings from a survey of 650 global banking decision-makers, marking a definitive shift in the sector towards agile and customer-focused banking. Moreover, the survey uncovers a transformative trend: banks are finally pivoting from entrenched mainframe systems to adopt AI and cloud technologies, spurred by the multiple headwinds they face of consumer demands, innovative new market disruption, and the competitive pressures of innovative technological advancements.

Modernisation and Transformation Trends:

  • Enduring Mainframes: Despite 89% of banking leaders identifying as innovators, 63% still operate on mainframe systems, confirming the mainframe’s resilience.
  • Cloud Migration to Increase from Generative AI injection: 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud
  • Generative AI Gaining Board-Level Support: A resounding 91% report their AI and cloud initiatives are endorsed by the board, signalling strategic prioritisation.
  • Navigating Skill Gaps: With 80% lacking a strategic framework for generative AI adoption, the need for upskilling is evident.
  • 45% of banks are already integrating generative AI technology into their technology stacks while a further 30% are in the early stages of looking at it.
  • Cloud as an Innovation Enabler: Flexibility and scalability are cited by 36% of respondents as key drivers for cloud migration, indicating a shift beyond cost concerns.

The enduring stronghold of mainframes in the banking sector is poised for a significant shift, thanks to the integration of generative AI into cloud migration strategies. NTT DATA's research reveals that 63% of banking decision-makers confirm generative AI is decisively facilitating the transition of banking applications to the cloud, indicating a transformative phase where mainframes’ resilience meets the agility of cloud computing.

25% of respondents also acknowledge a growing trend in cloud migration, propelled by AI advancements. This heralds a new era where the collaboration between AI’s potential to reinterpret legacy code and cloud technology's scalability is accelerating modernisation and transformation initiatives, suggesting that the longstanding reign of mainframes is approaching its horizon.

Kaz Nishihata, Director and Senior Executive Vice President at NTT DATA Group Corporation, commented: "Banks are not only evolving technologically but also culturally. The industry’s rapid adoption of AI and cloud is redefining business models and establishing a new norm in sector leadership. This technological tide is propelling banks toward a more intimate understanding of customer needs, delivering services that are faster, more secure, and uniquely tailored."

The research also found that the banking industry is rapidly embracing the transformative power of generative AI, with 45% of banks already incorporating it into their operations. Additionally, 30% are exploring its potential, signalling a proactive shift towards innovation. This adoption underscores the sector's commitment to future-proofing services and the desire for organisations to enhance their competitive edge in a fast-evolving digital landscape.

Nishihata adds, “The momentum for generative AI across the banking sector is a testament to the industry’s resolve to move beyond traditional mainframes, leveraging cloud environments to fortify security, enhance robustness, innovate, and boldly redefine. This transition promises a new era of innovation.”

To read the full report, visit "The Digital Horizon: Banking’s Shift from Mainframe to AI-Driven Cloud Infrastructure"

About the research

NTT DATA's survey canvasses a diverse array of banking professionals, from all global banking markets, and provides a 360-degree perspective on the sector's modernisation and journey towards innovation and transformation.

Demographics of Respondents:

  • Global Insights: Leaders from a broad geographic spectrum, including the United States, the United Kingdom, Japan, Germany, Spain, Italy, Mexico, and Brazil.
  • Institutional Scope: A cross-section from multinational banks to local banking institutions.
  • Expertise Range: Perspectives across IT, Operations, Innovation, and Strategy.

About NTT DATA

NTT DATA – a part of NTT Group – is a trusted global innovator of IT and business services headquartered in Tokyo. We help clients transform through consulting, industry solutions, business process services, IT modernisation and managed services. NTT DATA enables clients, as well as society, to move confidently into the digital future. We are committed to our clients’ long-term success and combine global reach with local client attention to serve them in over 50 countries. Visit us at nttdata.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240208750914/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye